Search details
1.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37789669
2.
RECAM-J 2023-Validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury.
Hepatol Res
; 2024 Apr 20.
Article
in English
| MEDLINE | ID: mdl-38642343
3.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37983642
4.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 39(5): 949-954, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38291715
5.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Article
in English
| MEDLINE | ID: mdl-36455517
6.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Article
in English
| MEDLINE | ID: mdl-37307798
7.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Article
in English
| MEDLINE | ID: mdl-37552968
8.
Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
Hepatol Res
; 53(1): 51-60, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36136893
9.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37020416
10.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37306040
11.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37231943
12.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Oncology
; 100(2): 65-73, 2022.
Article
in English
| MEDLINE | ID: mdl-34844247
13.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Article
in English
| MEDLINE | ID: mdl-36103846
14.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35080087
15.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34799975
16.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35633504
17.
Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy.
Int J Mol Sci
; 23(6)2022 Mar 20.
Article
in English
| MEDLINE | ID: mdl-35328778
18.
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Oncology
; 99(8): 518-527, 2021.
Article
in English
| MEDLINE | ID: mdl-33906189
19.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Liver Int
; 41(12): 2997-3008, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34250737
20.
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hepatol Res
; 51(8): 880-889, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33837620